In our analysis, 47 cases of IBD [pooled incidence rate of 0.37 per 1,000 patient-years (95% CI: 0.12, 0.61) for worst case scenario were reported in patients treated with IL-17 antagonists. Here, IL17A is linked to inflammatory bowel disease.